Annotation Detail
Information
- Associated Genes
- BRAF
- Associated Variants
-
BRAF D594K
BRAF D594K - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 patients with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6403
- Gene URL
- https://civic.genome.wustl.edu/links/genes/5
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2398
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Oxaliplatin
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 19603024
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Oxaliplatin | Resitance or Non-Reponse | true |